Shares of advanced nuclear company Oklo (NASDAQ: OKLO) moved higher this week, buoyed by a major partnership with tech giant Meta and a key regulatory approval for its subsidiary, Atomic Alchemy. The stock rose modestly on Monday and gained 4.6% in premarket trading Tuesday ahead of its Q4 2025 earnings report.
The partnership with Meta, announced in January, is a prepaid power deal to support a 1.2-gigawatt nuclear power campus in Pike County, Ohio. CEO Jacob DeWitte called Meta's involvement "a major step in moving advanced nuclear forward," providing a critical financial anchor for early-stage development. Analysts from BofA Securities noted it is "one of a few firm, binding partnerships today" in the nuclear industry.
Separately, Oklo's wholly-owned subsidiary, Atomic Alchemy, received its first-ever materials license from the U.S. Nuclear Regulatory Commission (NRC). The license allows the subsidiary to receive, store, process, and distribute isotopes—including Ra-226, Co-60, and Am-241—at its Idaho Radiochemistry Laboratory. This enables initial commercial sales, marking Oklo's first potential revenue stream, though the company remains pre-revenue overall.
Investor focus remains on Oklo's path to profitability and execution risks. The company is set to report full-year 2025 results, with analysts projecting a loss of $0.17 per share for Q4. Key concerns include regulatory hurdles and fuel execution, highlighted by Needham's Sean Milligan. Oklo's previous reactor license bid was rejected by the NRC in 2022, and its core advanced reactors still await NRC approval before it can sell electricity.
To bolster its fuel strategy, Oklo formed a joint venture with Centrus Energy in Ohio for deconversion services of high-assay low-enriched uranium (HALEU). The company also signed a new agreement with the U.S. Department of Energy to support its first reactor at Idaho National Laboratory. Backed by $1.18 billion in cash, Oklo is targeting commercial nuclear power production by late 2027 or 2028.
